Fingerprint
Dive into the research topics of 'Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: A Gynecologic Oncology Group study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically